celecoxib and ml-3000
celecoxib has been researched along with ml-3000 in 14 studies
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Dannhardt, G; Scholz, M; Ulbrich, HK | 1 |
| Dannhardt, G; Lindbom, L; Mattern, A; Scholz, M; Soehnlein, O; Ulbrich, HK | 1 |
| Aparoy, P; Chandramohan Reddy, T; Kalangi, SK; Kumar Reddy, K; Reddanna, P | 1 |
| Bensdorf, K; Guo, C; Gust, R; Huang, W; Liu, H; Liu, W; Qian, H; Rubner, G; Wang, Y; Wellner, A; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Dannhardt, G; Geffken, D; Hansen, FK; Khankischpur, M; Mesaros, R; Tolaymat, I | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afrasiabi, Z; Choudhury, A; Fresco, VM; Ghatak, S; Khetmalas, M; Markwald, RR; Misra, S; O'Brien, P; Padhye, S; Swamy, KV; Vyas, A; Zambre, A | 1 |
| Bandresh, R; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN | 1 |
| El Kerdawy, AM; Gedawy, EM; Kassab, AE | 1 |
| Bhatti, R; Kaur, J; Kumari, P; Singh, P | 1 |
| Alvaro-Gracia, JM | 1 |
| Klein, T; Pushkareva, MA; Shephard, P; Sud'ina, GF | 1 |
| Balansky, R; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Nikolov, M; Steele, VE | 1 |
Reviews
2 review(s) available for celecoxib and ml-3000
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Topics: Acetates; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Combinations; Gastrointestinal Diseases; Humans; Isoenzymes; Lipoxygenase Inhibitors; Long-Term Care; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Sulfonamides | 2004 |
Other Studies
12 other study(ies) available for celecoxib and ml-3000
| Article | Year |
|---|---|
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
Topics: Azoles; Cyclooxygenase Inhibitors; Free Radical Scavengers; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Models, Molecular; Selenium Compounds | 2008 |
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Free Radical Scavengers; Hydroxyl Radical; Lipoxygenase Inhibitors; Macrophage-1 Antigen; Mice; Neutrophils; Peritonitis; Sulfhydryl Compounds; Thiazoles | 2009 |
Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Topics: Arachidonate 5-Lipoxygenase; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Lipoxygenase Inhibitors; Models, Chemical; Models, Molecular | 2010 |
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Edema; Female; Male; Mice; Pyrroles | 2011 |
Efficient synthesis and 5-LOX/COX-inhibitory activity of some 3-hydroxybenzo[b]thiophene-2-carboxylic acid derivatives.
Topics: Arachidonate 5-Lipoxygenase; Carboxylic Acids; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Lipoxygenase Inhibitors; Protein Binding; Structure-Activity Relationship; Thiophenes | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Topics: Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Hydrazones; Lipoxygenase Inhibitors; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2014 |
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Indolizines; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship; Ulcer | 2017 |
Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Arachidonate 5-Lipoxygenase; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Lipoxygenase Inhibitors; Male; Mice; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides | 2020 |
Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Humans; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Tartrates | 2021 |
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.
Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acid; Blood; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; Humans; Indoles; Isoenzymes; Lipoxygenase Inhibitors; Molecular Structure; Neutrophils; Pyrazoles; Pyrroles; Random Allocation; Sulfonamides | 2008 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxygenase 2 Inhibitors; Enzyme Inhibitors; Female; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Precancerous Conditions; Pyrroles; Smoking; Survival Rate; Toxicity Tests, Subchronic | 2015 |